Wall Street Digest: Aware, Inc. (AWRE), Cliffs Natural Resources (CLF), Ubic Inc (UBIC)

Aware, Inc. (NASDAQ:AWRE) appears to be enjoying the boom in the biometric market. The gains in the biometric space could easily be seen in the company’s latest quarterly results. The company posted 40% increase in revenue to $6 million. As if that was not good enough, the biometric technology provider reported a net income of $2.6 million. That was far much better than a loss of $1.2 million suffered in the like quarter a year earlier.

Commenting on the highly positive results, CFO and co-CEO, Rick Moberg, said that several factors came into play in the quarter to boost the performance. He mentioned that they were able to close significant opportunities in the quarter. Additionally, the executive said their NEXA product line had started to generate revenue, thereby boosting the top line.

The management of Aware, Inc. (NASDAQ:AWRE) expects more and better opportunities in the future as governments around the world tap into biometric technology to enhance security at airports and in other installations.

There appears to be no end in sight for the troubles facing the coal and iron ore industries, and Cliffs Natural Resources Inc (NYSE:CLF) is one of those bearing the brunt. Analysts are beginning to worry about the future of the industries, which is why Citigroup Inc (NYSE:C) downgraded Cliffs Natural Resources Inc (NYSE:CLF). The firm cited that the fall in iron ore prices was likely to continue, at least, in the next two years.

As such, Citigroup now rates Cliffs Natural Resources Inc (NYSE:CLF) as a “Sell” down from “Neutral”. The firm set $5 target price on the stock. Shares of Cliffs Natural Resources are currently trading in the region of $9, having declined more than 65% this year.

Ubic Inc (ADR) (NASDAQ:UBIC) now sees growth opportunity in the pharmaceutical space and the company wants to expand there. The company said that its Big Data solutions in the pharmaceutical will help players there to achieve better analysis of clinical trial data in the drug development.

As it moves to tap the opportunities in the pharmaceutical segment, Ubic Inc (ADR) (NASDAQ:UBIC) announced the appointment of Masahiro Takeuchi to be its technical advisor such matters.

About the Author

Barry is a senior journalist at Us Markets Daily. He reports, shoots and edits many of his own stories by himself.

Leave A Response